(3)今年年初,Mapp等几家生物制药公司获得了一笔五年期最高2800万美元的奖金,用于一个抗击埃博拉病毒的项目。这笔奖金是由美国国立卫生研究院(National Institutes of Health)提供的,旨在通过全球合作开发出抗击埃博拉病毒和青猴病、苏丹亚型埃博拉病毒、拉沙病毒等出血热病毒的鸡尾酒疗法。这笔奖金意在激励所有参与方贡献抗体,以开发最佳治疗方案。
4) That grant was awarded after research from the U.S. Army Medical Research Institute of Infectious Diseases showed that a mix of antibodies can stop the Ebola virus. Scientists were able to successfully treat infected primates following the onset of disease symptoms. Around that time, Mapp had consolidated its antibody programs with Canada-based Defyrus, aiming to streamline the development of more potent treatments.
(4)就在这笔奖金发放之前,美国陆军传染病医学研究院(U.S. Army Medical Research Institute of Infectious Diseases)的研究显示,一系列抗体的组合可以阻止埃博拉病毒的恶化。在试验中,科学家们已经成功地治疗了开始出现病毒症状的灵长类动物。与此同时,Mapp公司也已经和加拿大的Defyrus公司展开合作,以优化更多专利疗法的研发过程。
5) The potential success of Mapp’s drug in treating Americans infected with the disease does raise questions about the limited use of experimental treatments after hundreds of Africans have died. Bloomberg reported the Food and Drug Administration can approve an emergency application to provide access to unapproved drugs, a request that can be granted within 24 hours.
【人类需要了解的有关抗埃博拉病毒药物的五件事】相关文章:
最新
2020-09-15
2020-09-15
2020-09-15
2020-09-15
2020-09-15
2020-09-15